Biotechs often need several years to realize their visions, even after they have a drug approved for the first time. There's typically plenty of upside in store for enterprising and patient investors.Here are two such opportunities that are ripe for buying today, provided that you're willing to hold on to your shares for at least five years.1. CRISPR TherapeuticsWith a bunch of gene therapy and gene editing programs in clinical trials, CRISPR Therapeutics (CRSP 0.85%) has an impressive resume already, but i ...

CRISPR Therapeutics AG (NASDAQ:CRSP) Guggenheim Inaugural Healthcare Innovation Conference November 12, 2024 2:00 PM ET Company Participants Samarth Kulkarni - CEO and Chairman Conference Call Participants Debjit Chattopadhyay - Guggenheim Partners Debjit Chattopadhyay Good afternoon and thank you for joining us at Guggenheim's Inaugural Healthcare Innovations Conference. I am Debjit and one of the therapeutic analysts here. And joining me today is Samarth Kulkarni, CEO and Chairman of CRISPR Therapeutics. ...

一、涉及公司 CRISPR Therapeutics AG (NASDAQ:CRSP)[1] 二、核心观点与论据 （一）公司发展历程与重要里程碑 1. 公司成立10年，致力于利用CRISPR技术制造药物，为重病患者带来变革性治疗[3]。 2. 已达成一个非常重要的里程碑，即世界上首个获批的CRISPR药物CASGEVY，用于镰状细胞贫血和地中海贫血，目前由合作伙伴Vertex推出[3]。 （二）公司的研发管线 1. 构建了多元化的研发管线，不仅有CASGEVY，还包括体外（ex - vivo）和体内（in - vivo）项目[4]。 2. 体外项目方面，有针对CD - 19的同类最佳的同种异体CAR - T（CTX - 112），正在开发用于肿瘤和自身免疫适应症[4]。 3. 体内项目方面，有可用于肝脏编辑的直接注射、静脉注射（IV），针对如LPA和ANGP TL3等目标，其中LPA在未来几年将是制药领域非常重要的目标[5]。 三、其他重要但可能被忽略的内容 无（文档未涉及）

CRISPR Therapeutics (CRSP -5.91%) made a name for itself by pioneering advanced gene therapies made with technologies that didn't exist a generation ago. Now, its challenge is to build on its prior successes to become a biotech powerhouse and prove to investors that it isn't a one-trick pony.The next three years will be critical for both of those things. Here's what to expect.This bird is leaving the nestBy late 2027, CRISPR will be a larger biotech, with much more revenue, more collaborators, and a much bi ...

ZUG, Switzerland and BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that Samarth Kulkarni, Ph.D., Chief Executive Officer and Chairman of CRISPR Therapeutics, will present at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024, at 4:00 p.m. GMT. A live webcast of the fireside chat will be available on the "Events & Presentations" page ...

If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there.The group is for both novice and experienced biotech investors. It provides catalysts to look out for and buy and sell ratings. It also provides product sales and forecasts ...

Shares of CRISPR Therapeutics AG (CRSP) have gained 11.4% over the past four weeks to close the last trading session at $50.36, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $81.96 indicates a potential upside of 62.8%.The mean estimate comprises 24 short-term price targets with a standard deviation of $34.57. While the lowest estimate of $30 indicates a 40.4% decline from the ...

公司财务状况 - 2024年第三季度每股亏损1.01美元低于Zacks共识预期的每股亏损1.33美元较去年同期每股亏损1.41美元有所收窄总营收虽可忽略不计但全部来自补助收入为60万美元远低于Zacks共识预期的640万美元去年同期无营收 [1] - 研发费用同比下降9%至8220万美元因外部可变研发和制造成本降低一般及行政费用本季度同比下降5%至1740万美元合作费用本季度为1120万美元同比下降52% [2] - 截至2024年9月30日公司拥有现金现金等价物可出售证券和应收账款19亿美元较2024年6月30日的20亿美元有所减少 [3] 公司股票表现 - 公司股票今年迄今已下跌19.5%而行业下跌3.8% [3] 公司产品管线及其他进展 - 公司与合作伙伴Vertex的一次性体外基因疗法Casgevy于2023年末2024年初在美国和欧洲获批用于两种血液疾病VRTX在2021年协议条款下领导Casgevy的全球开发和商业化并得到公司支持 [5] - 自10月中旬以来全球已激活超过45个授权治疗中心VRTX在治疗第一名患者后录得200万美元的Casgevy产品收入且在财报电话会议上提到Casgevy推出情况良好 [6] - 除Casgevy外公司正在开发CRISPR候选产品以创建新型CAR - T细胞疗法目前正专注于优先开发下一代CAR - T疗法候选产品CTX112和CTX131分别处于I/II期研究预计CTX131研究的初步数据将于2024年底出炉 [7] - 管理层正在探索这些下一代候选产品在其他适应症中的潜力8月公司宣布已启动两项新临床研究分别评估CTX131用于血液系统恶性肿瘤CTX112用于系统性红斑狼疮还打算评估CTX112在其他自身免疫适应症中的应用 [8] - 管理层也在关注体内候选产品公司正在分别针对ANGPTL3和脂蛋白(a)的I期临床研究中研究其前两个体内候选产品CTX310和CTX320 [9] - 管理层打算再用两个项目CTX340和CTX450进一步扩展体内产品线已启动这两个候选产品的IND - enabling研究预计2025年下半年开始临床研究 [10] 公司排名及其他股票参考 - 公司目前Zacks排名为2(买入) [11] - 同行业其他排名靠前的股票如Amicus Therapeutics和Biogen目前Zacks排名均为2过去60天Amicus Therapeutics的2024年每股收益预期从21美分升至22美分2025年每股收益预期从50美分升至53美分今年迄今FOLD股票已下跌17.3%过去四个季度中有三个季度盈利超出预期一次未达预期平均惊喜为23.96% [12] - 过去60天Biogen的2024年每股收益预期从16.12美元升至16.36美元2025年每股收益预期从17.09美元升至17.15美元今年迄今BIIB股票已上涨40.9%过去四个季度中有三个季度盈利超出预期一次未达预期平均惊喜为9.99% [13]

CRISPR Therapeutics AG (CRSP) came out with a quarterly loss of $1.01 per share versus the Zacks Consensus Estimate of a loss of $1.33. This compares to loss of $1.41 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 24.06%. A quarter ago, it was expected that this company would post a loss of $1.37 per share when it actually produced a loss of $1.49, delivering a surprise of -8.76%.Over the last four quarters, the company has s ...

财务状况 - 公司2021年第四季度营收为1.38亿美元，同比增长18%。[1] - 公司2021年全年营收为5.04亿美元，同比增长22%。[1] - 公司2021年第四季度毛利率为78.5%，同比提高1.5个百分点。[1] - 公司2021年全年毛利率为77.9%，同比提高1.1个百分点。[1] 业务发展 - 公司在2021年第四季度新增了超过1,000家付费客户，总付费客户数达到约15,000家。[1] - 公司在2021年全年新增了超过4,000家付费客户。[1] - 公司在2021年第四季度新增了超过100家大型企业客户，总大型企业客户数达到约1,000家。[1] - 公司在2021年全年新增了超过300家大型企业客户。[1] 未来展望 - 公司预计2022年第一季度营收将达到1.38亿至1.40亿美元，同比增长约15%至17%。[1] - 公司预计2022年全年营收将达到5.80亿至5.90亿美元，同比增长约15%至17%。[1] - 公司将继续专注于产品创新和客户服务,以推动未来增长。[1]